Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Difluprednate ophthalmic emulsion is used for the treatment of inflammation and pain associated with ocular surgery.
Efficacy of difluprednate has been evaluated in 2 randomized, double-blind, placebo-controlled studies in patients who had undergone cataract surgery. In these studies, patients with an anterior chamber cell grade of 2 or higher (a cell count of 11 or higher) after cataract surgery were randomized to receive either difluprednate 0.05% ophthalmic emulsion (1 drop 2 or 4 times daily) or vehicle for 14 days, beginning the day after surgery. At 8 days postoperatively, reduction of ocular inflammation (anterior chamber cell clearing) or absence of ocular pain was achieved in 22 or 58%, respectively, of patients receiving difluprednate (1 drop 4 times daily) compared with 7 or 27%, respectively, of those receiving vehicle. At 15 days postoperatively, anterior chamber cell clearing or absence of ocular pain was achieved in 41 or 63%, respectively, of patients receiving difluprednate (1 drop 4 times daily) compared with 11 or 35%, respectively, of those receiving vehicle.
Dosage and Administration
Difluprednate is applied topically in the conjunctival sac of the affected eye(s) as an ophthalmic emulsion. Care should be taken to avoid contamination of the emulsion container.
Patients should refrain from wearing contact lenses during therapy with difluprednate ophthalmic emulsion unless specifically directed by a clinician.
Difluprednate ophthalmic emulsion may be used in conjunction with other topical ophthalmic drugs such as β-adrenergic blocking agents, carbonic anhydrase inhibitors, α-agonists, cycloplegics, and mydriatics. If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered 10 minutes apart from difluprednate administration.
The recommended initial adult dosage of difluprednate for the treatment of postoperative inflammation and pain in patients who have undergone ocular surgery is 1 drop of a 0.05% emulsion in the affected eye(s) 4 times daily, beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period. After 2 weeks of therapy, dosage should be reduced to 1 drop twice daily for 1 week and then gradually tapered according to response.
No special population recommendations at this time.
Most active viral diseases of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, and varicella [chickenpox]); mycobacterial infection of the eye; and fungal diseases of ocular structures.
Known hypersensitivity to difluprednate, other corticosteroids, or any ingredient in the formulation.
Glaucoma (with optic nerve damage and defects in visual acuity and fields of vision) may occur with long-term use of corticosteroids. Corticosteroids should be used with caution in patients with glaucoma. Intraocular pressure should be monitored if difluprednate is used for 10 days or longer.
Posterior subcapsular cataract formation also may occur with use of corticosteroids.
Wound Healing Complications
Use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation. In conditions causing thinning of the cornea or sclera, perforations have been reported following use of topical corticosteroids.
Careful monitoring, including slit-lamp biomicroscopy and fluorescein staining when appropriate, is necessary in patients requiring difluprednate therapy for longer than 28 days.
Increased Susceptibility to Infections
Prolonged use of corticosteroids may increase the risk of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or exacerbate existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.
Use of ophthalmic corticosteroids may prolong and exacerbate ocular viral infections (e.g., herpes simplex). Difluprednate should be used with extreme caution in patients with a history of herpes simplex virus infection.
Fungal infections of the cornea are particularly prone to develop following long-term use of ophthalmic corticosteroids. The possibility of fungal infection must be considered in patients receiving corticosteroids who present with persistent corneal ulceration. Fungal culture should be obtained when appropriate.
Systemically administered corticosteroids distribute into milk and may suppress growth, interfere with endogenous corticosteroid production, or cause other adverse effects. It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in milk; caution if used in nursing women.
Safety and efficacy not established in pediatric patients.
No substantial differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Adverse ocular effects reported in 5-15% of patients receiving difluprednate include corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Adverse ocular effects reported in 1-5% of patients include reduced visual acuity, punctate keratitis, eye inflammation, and iritis.
No formal drug interaction studies have been performed to date.